Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Stock Chart & Stats
$18.29
-$0.43(-1.58%)
At close: 4:00 PM EST
$18.29
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$14.43 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)1.13M
Market Cap
$572.29M
Enterprise Value$1.13B
Total Cash (Recent Filing)$202.17M
Total Debt (Recent Filing)$461.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 25, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding31,289,968
10 Day Avg. Volume1,155,226
30 Day Avg. Volume1,130,968
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)3.01
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue64.47
Enterprise Value/Gross Profit65.07
Enterprise Value/Ebitda-17.22
Forecast
1Y Price Target
$57.50Price Target Upside214.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.82
Revenue Forecast (FY)$52.27M
Bulls Say, Bears Say
Bulls Say
Commercial Partnerships And Market ExpansionExclusive regional distribution agreements and multiple commercialization deals support accelerated geographic expansion and diversified revenue opportunities.
Direct-to-consumer MarketingPlanned direct-to-consumer campaign featuring a high-profile spokesperson is likely to raise public awareness and stimulate patient demand for the novel presbyopia eye drop.
Prescriber Adoption And SamplingExtensive sampling to eye care professionals and strong early prescriber trial activity indicate growing commercial traction and potential for increasing repeat prescriptions.
Bears Say
Adverse-event Headline And Clinical Compliance RiskA reported retinal tear and the lack of a documented pre-treatment retinal exam in that case could erode prescriber and patient confidence and create headline-driven adoption headwinds.
Promotion-to-prescription Conversion RiskMarket appears promotionally sensitive, and consumer marketing may not immediately translate into sustained prescription volumes and higher refill rates, posing a performance risk.
Script Conversion Expectations And Investor SentimentInvestor expectations for paid script volumes versus peer comparisons may be elevated, and misinterpretation of conversion metrics could drive further stock volatility if actual conversion remains below forecasts.
LENZ Therapeutics News
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $14.43 and its highest was $50.40 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $572.29M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 66 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.102.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -0.96.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 31,289,968 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went down -23.458%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.50 (214.38% Upside)
$57.50 (214.38% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $289.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.5%
Last 30 Days ▲ 38.4%
Last 30 Days ▲ 38.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.34%
12-Months-Change
Fundamentals
Return on Equity
-28.78%
Trailing 12-Months
Asset Growth
-5.94%
Trailing 12-Months
Company Description
LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for LENZ, highlighted by the successful early launch of VIZZ and significant financial backing. While there were minor issues with transient side effects and initial retail availability, the overall sentiment was bolstered by strong prescription metrics, high awareness among doctors, and strategic partnerships.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$57.50
▲(214.38% Upside)
Technical Analysis
Ownership Overview
15.14% Insiders
11.21% Mutual Funds
61.45% Other Institutional Investors
4.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---